TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24915261

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (adjustable or nonadjustable banding, vertical banded gastroplasty, gastric bypass)
Number of subjects: 603

Group type: COMPARATOR
Intervention: Usual obesity and diabetes care (control group)
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 603
Study: 24916038

Group type: EXPERIMENTAL
Intervention: Adoptive immunotherapy using ex vivo-expanded cytokine-induced killer (CIK) cells, administered intravenously 10 times, every week for 5 weeks and then every other week for 10 weeks.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Adoptive immunotherapy using ex vivo-expanded cytokine-induced killer (CIK) cells.
Number of subjects: 20
Study: 24916144

Group type: EXPERIMENTAL
Intervention: Electrical Cardiometry (EC)
Number of subjects: 374
Study: 24916506

Group type: EXPERIMENTAL
Intervention: R-FC (rituximab, fludarabine, and cyclophosphamide)
Number of subjects: 834

Group type: COMPARATOR
Intervention: FC (fludarabine and cyclophosphamide)
Number of subjects: 834
Study: 24916507

Group type: EXPERIMENTAL
Intervention: Heme-bound iron (hemin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enforced expression of erythroid Krüppel-like factor (EKLF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hemin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SCD patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Markers of iron overload
Number of subjects: 0
Study: 24916770

Group type: EXPERIMENTAL
Intervention: Navitoclax 325 mg co-administered with gemcitabine 1,000 mg/m(2) (21-day dosing schedule)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Navitoclax doses escalated from 150 to 425 mg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Navitoclax 325 mg with gemcitabine 1,000 mg/m(2)
Number of subjects: 46
Study: 24916771

Group type: EXPERIMENTAL
Intervention: PX-866 and cetuximab
Number of subjects: 11
Study: 24916908

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy preparation through TIPS trial
Number of subjects: 17
Study: 24917216

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Hyperglycemia
Number of subjects: 645
Study: 24917420

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 30
Study: 24917940

Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg once daily
Number of subjects: 936

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 936
Study: 24917966

Group type: EXPERIMENTAL
Intervention: Antibiotics (H. pylori-positive patients)
Number of subjects: 589

Group type: COMPARATOR
Intervention: Placebo (H. pylori-positive patients)
Number of subjects: 589

Group type: COMPARATOR
Intervention: Placebo (H. pylori-negative controls)
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg b.d. for 7 days, followed by 40 mg o.d. for 8 weeks (all patients)
Number of subjects: 589
Study: 24918167

Group type: EXPERIMENTAL
Intervention: Simvastatin treatment in patients with SLCO1B1 genotype rs4149056T>C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic recommendations based on SLCO1B1 genotype
Number of subjects: 0
Study: 24918220

Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 2233

Group type: COMPARATOR
Intervention: Comparator
Number of subjects: 2233
Study: 24918790

Group type: EXPERIMENTAL
Intervention: Albiglutide (30 mg single-dose; 30 to 50 mg multiple-dose)
Number of subjects: 1154

Group type: EXPERIMENTAL
Intervention: Albiglutide (30 to 50 mg)
Number of subjects: 1154

Group type: EXPERIMENTAL
Intervention: Albiglutide
Number of subjects: 1154
Study: 24918945

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Burn size, age, body fat percentage
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Time postburn, lean mass
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 61
Study: 24918982

Group type: EXPERIMENTAL
Intervention: TTD cohort
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: TTD cohort (patients who died during follow-up)
Number of subjects: 25
Study: 24919462

Group type: EXPERIMENTAL
Intervention: Dacetuzumab (SGN-40), 8 mg/kg/week, administered intravenously for up to 12 cycles
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Dacetuzumab (SGN-40)
Number of subjects: 46
Study: 24919691

Group type: EXPERIMENTAL
Intervention: HIV-infected mothers' milk
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Low concentrations of DSLNT in 4-d milk samples
Number of subjects: 82
Study: 24919854

Group type: EXPERIMENTAL
Intervention: LY2835219
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LY2835219 in combination with gemcitabine
Number of subjects: 0
Study: 24919941

Group type: EXPERIMENTAL
Intervention: LIFEspan service delivery model
Number of subjects: 0
Study: 24920166

Group type: EXPERIMENTAL
Intervention: Clock Drawing Test (CDT) administered at baseline and annually thereafter
Number of subjects: 3845
Study: 24920528

Group type: EXPERIMENTAL
Intervention: Hypersensitive IBS patients
Number of subjects: 188

Group type: COMPARATOR
Intervention: Normosensitive IBS patients
Number of subjects: 188
Study: 24920586

Group type: EXPERIMENTAL
Intervention: Single-agent ixazomib 0.24 to 2.23 mg/m(2) (days 1, 4, 8, 11; 21-day cycles)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Single-agent ixazomib 0.24 to 2.23 mg/m(2)
Number of subjects: 60
Study: 24920921

Group type: EXPERIMENTAL
Intervention: Concurrent thoracic radiotherapy and erlotinib
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lung dosimetric parameters
Number of subjects: 24
Study: 24921388

Group type: EXPERIMENTAL
Intervention: Action potentials (spiking)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Combined decoding of all LFPs
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: LFPs (200-400 Hz)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: LFPs (0-7, 10-40, 50-65 Hz)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Spiking signals
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: LFP signals
Number of subjects: 2
Study: 24923295

Group type: EXPERIMENTAL
Intervention: AML+13 patients
Number of subjects: 34

Group type: COMPARATOR
Intervention: ELN Intermediate-II patients
Number of subjects: 34
Study: 24923356

Group type: EXPERIMENTAL
Intervention: Osteoprotegerin (OPG) levels in Turner syndrome
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Osteoprotegerin (OPG) levels in Turner syndrome older than 50 years
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Osteoprotegerin (OPG) levels in Turner syndrome on antihypertensive medication
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Correlation of OPG levels with aortic diameter in Turner syndrome
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Correlation of OPG levels with body surface area (BSA), weight, and plasma oestradiol levels in Turner syndrome
Number of subjects: 99

Group type: COMPARATOR
Intervention: Osteoprotegerin (OPG) levels in controls
Number of subjects: 99
Study: 24923792

Group type: EXPERIMENTAL
Intervention: DMPA users
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: DMPA users with calcium intake ≥ 1 g/day
Number of subjects: 54

Group type: COMPARATOR
Intervention: Non-hormonal contraceptive users
Number of subjects: 54
Study: 24924750

Group type: EXPERIMENTAL
Intervention: Caproic acid (C6)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lauric acid (C12)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oleic acid (C18:1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blank solutions with mineral oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NEFA emulsions
Number of subjects: 0
Study: 24924798

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 617

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Both laparoscopic and open surgery
Number of subjects: 617
Study: 24925211

Group type: EXPERIMENTAL
Intervention: Ofatumumab and bendamustine
Number of subjects: 10
Study: 24925526

Group type: EXPERIMENTAL
Intervention: Bradykinin (BK) 400 ng/min
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Fluconazole (0.4 µmol·min(-1)·l(-1))
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Tetraethylammonium chloride (TEA; 1 µmol/min)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: N(G)-monomethyl-L-arginine (L-NMMA, 8 µmol/min)
Number of subjects: 33
Study: 24926886

Group type: EXPERIMENTAL
Intervention: OffRoad Re-Entry Catheter System
Number of subjects: 92
Study: 24926953

Group type: EXPERIMENTAL
Intervention: Metreleptin (0.06-0.24 mg/kg/d) administered for 24 months
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Baseline measurements
Number of subjects: 82

Group type: COMPARATOR
Intervention: Linear regression in obesity
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Linear regression in lipodystrophy
Number of subjects: 82
Study: 24927802

Group type: EXPERIMENTAL
Intervention: In-person results delivery by a genetic counselor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Online results delivery through the testing company's website
Number of subjects: 0
Study: 24927855

Group type: EXPERIMENTAL
Intervention: Edwards SAPIEN XT™ in PREVAIL JAPAN cohort
Number of subjects: 301

Group type: COMPARATOR
Intervention: Edwards SAPIEN XT™ in Massy cohort
Number of subjects: 301
Study: 24927856

Group type: EXPERIMENTAL
Intervention: Otlertuzumab (10 or 20 mg/kg) in combination with rituximab (375 mg/m(2)) and bendamustine (90 mg/m(2)); administered IV on days 1 and 15 for up to six 28-day cycles.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Otlertuzumab (10 or 20 mg/kg) in combination with rituximab and bendamustine;
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Otlertuzumab in combination with rituximab and bendamustine;
Number of subjects: 12
Study: 24928474

Group type: EXPERIMENTAL
Intervention: One breakfast consumed
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: Two breakfasts consumed
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: Three or more breakfasts consumed
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: No breakfast consumed
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: BMI percentile relationship
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: Breakfast consumption by grade
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: No breakfast among obese youth
Number of subjects: 651
Study: 24928772

Group type: EXPERIMENTAL
Intervention: carlumab + docetaxel (n=15)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: carlumab + gemcitabine (n=12)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: carlumab + paclitaxel + carboplatin (n=12)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: carlumab + PLD (n=14)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: carlumab (alone)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: carlumab + chemotherapy (all arms)
Number of subjects: 19
Study: 24929258

Group type: EXPERIMENTAL
Intervention: Normal progesterone levels (≤4.77 nmol/L or ≤1.5 ng/mL)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Elevated progesterone levels (>4.77 nmol/L or >1.5 ng/mL)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Elevated progesterone levels (meta-analysis)
Number of subjects: 158
Study: 24929484

Group type: COMPARATOR
Intervention: Volatile organic compounds (VOCs) in bile analyzed using selected ion flow tube mass spectrometry (SIFT-MS).
Number of subjects: 96

Group type: COMPARATOR
Intervention: Predictive model for pancreatic cancer diagnosis based on VOC levels.
Number of subjects: 96
Study: 24929893

Group type: EXPERIMENTAL
Intervention: Aerobic exercise + weight loss (AEX + WL)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Weight loss (WL)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 33
Study: 24930123

Group type: EXPERIMENTAL
Intervention: 3D volumetric ICE imaging
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 3D volumetric ICE imaging with color Doppler
Number of subjects: 15
Study: 24930531

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study: 24930597

Group type: EXPERIMENTAL
Intervention: Objectively measured energy intake (EI) using doubly labeled water (DLW) assessment
Number of subjects: 253

Group type: COMPARATOR
Intervention: Self-reported habitual caloric intake based on a food frequency measure
Number of subjects: 253

Group type: COMPARATOR
Intervention: Baseline resting metabolic rate (RMR)
Number of subjects: 253
Study: 24931753

Group type: EXPERIMENTAL
Intervention: Arctium lappa (Lappa) prescribed in potencies from 6c to 1M over 6 months
Number of subjects: 34
Study: 24932181

Group type: EXPERIMENTAL
Intervention: Montelukast monotherapy
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Montelukast combined with ICS
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Montelukast add-on therapy
Number of subjects: 328
Study: 24932223

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 51
Study: 24932797

Group type: EXPERIMENTAL
Intervention: Abnormal CSE
Number of subjects: 174

Group type: COMPARATOR
Intervention: Normal CSE
Number of subjects: 174
Study: 24934200

Group type: EXPERIMENTAL
Intervention: Blast plus impact complex TBI
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Non-blast related TBI
Number of subjects: 255

Group type: COMPARATOR
Intervention: Blast-exposed controls
Number of subjects: 255

Group type: COMPARATOR
Intervention: Non-blast-exposed controls
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Combat exposure intensity
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Overall outcomes
Number of subjects: 255
Study: 24934364

Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: mRNA expression levels of CK-18, CK-19, and CEA
Number of subjects: 70

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 70
Study: 24934501

Group type: EXPERIMENTAL
Intervention: Breastfeeding (mean duration 7.2 months)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Non-breastfeeding
Number of subjects: 181
Study: 24934506

Group type: EXPERIMENTAL
Intervention: Fast acetylator genotype in Cohort 1 (type 1 diabetes)
Number of subjects: 9813

Group type: EXPERIMENTAL
Intervention: Top signal rs4921914 in Cohort 2 (without diabetes)
Number of subjects: 9813

Group type: EXPERIMENTAL
Intervention: Fast acetylator genotype
Number of subjects: 9813
Study: 24934522

Group type: EXPERIMENTAL
Intervention: Fontan procedure
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Elevated brain natriuretic peptide (>21 pg/mL) and low Child Health Questionnaire physical summary score (<44)
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Child Health Questionnaire physical summary score
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Child Health Questionnaire psychosocial summary score
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: SF-36 physical aggregate score
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: SF-36 mental aggregate score
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Additional cardiac surgery
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Catheter intervention
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Arrhythmia requiring treatment
Number of subjects: 546
Study: 24935348

Group type: EXPERIMENTAL
Intervention: Clinical Dehydration Scale (CDS)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Urine sodium/potassium ratio
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Urine sodium
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Fractional sodium excretion
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Serum bicarbonate
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Creatinine measurements
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Heart rate
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure
Number of subjects: 216
Study: 24936168

Group type: EXPERIMENTAL
Intervention: High-intensity proactive service
Number of subjects: 586

Group type: COMPARATOR
Intervention: Low-intensity reactive service
Number of subjects: 586
Study: 24938849

Group type: EXPERIMENTAL
Intervention: Cocaine cue exposure
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Response inhibition cues
Number of subjects: 51
Study: 24939214

Group type: EXPERIMENTAL
Intervention: Famitinib 25 mg/d
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Famitinib 25 mg/d with elevated TSH
Number of subjects: 28
Study: 24940525

Group type: EXPERIMENTAL
Intervention: Vilazodone 40 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24940526

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (combined Lactobacillus rhamnosus strain GG and Bifidobacterium animalis subsp. lactis strain Bb12)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 65
Study: 24942210

Group type: EXPERIMENTAL
Intervention: Bevacizumab (7.5 mg/kg every 3 weeks)
Number of subjects: 162
Study: 24944232

Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG) 50 mg plus abacavir/lamivudine (600/300 mg) once daily
Number of subjects: 13
Study: 24944546

Group type: EXPERIMENTAL
Intervention: Acute sodium citrate supplementation (0.5 g kg(-1) administered 120 min pre-trial)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Chronic sodium citrate supplementation (0.1 g∙kg(-1) for three days and 0.3 g kg(-1) on the fourth day 120 min pre-trial)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Acute placebo (PLC-A)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Chronic placebo (PLC-C)
Number of subjects: 10
Study: 24944934

Group type: EXPERIMENTAL
Intervention: Oral anti-diabetic drugs (OADs)
Number of subjects: 6168

Group type: EXPERIMENTAL
Intervention: Insulin (±OADs)
Number of subjects: 6168

Group type: EXPERIMENTAL
Intervention: Diabetes complications
Number of subjects: 6168

Group type: EXPERIMENTAL
Intervention: Glycaemic control
Number of subjects: 6168

Group type: EXPERIMENTAL
Intervention: Barriers to insulin therapy
Number of subjects: 6168

Group type: EXPERIMENTAL
Intervention: Need for structured intervention
Number of subjects: 6168
Study: 24948033

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS) with Carotid WALLSTENT plus FilterWire EZ Embolic Protection System
Number of subjects: 1025
Study: 24948349

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0
Study: 24948692

Group type: EXPERIMENTAL
Intervention: Oral forodesine at a dose of 200 mg daily
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 144
Study: 24948702

Group type: EXPERIMENTAL
Intervention: Empirical treatment
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Pre-emptive treatment
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Targeted treatment
Number of subjects: 510

Group type: COMPARATOR
Intervention: Posaconazole prophylaxis
Number of subjects: 510
Study: 24949622

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavior therapy (ICBT) for 12 weeks with therapist support.
Number of subjects: 21
Study: 24949937

Group type: EXPERIMENTAL
Intervention: Citalopram monotherapy
Number of subjects: 2868
Study: 24950186

Group type: EXPERIMENTAL
Intervention: Conditioned Pain Modulation (CPM) assessed by the cold pressor test (CPT)
Number of subjects: 34
Study: 24950352

Group type: EXPERIMENTAL
Intervention: First booster vaccination with Encepur(®)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Control group (subjects who had already received their booster prior to enrollment)
Number of subjects: 323
Study: 24950666

Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa (9-60 U/kg body weight, every 2 weeks)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa
Number of subjects: 31
Study: 24950779

Group type: EXPERIMENTAL
Intervention: Flutamide (125 mg/day for 6 weeks)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59
Study: 24950819

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the nucleus accumbens (Acb) from M1 to M5
Number of subjects: 6

Group type: COMPARATOR
Intervention: Deep brain stimulation (DBS) of the caudate nucleus for nonresponders between M5 and M9
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Extension phase with stimulation of the Acb target for all patients
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Acb stimulation
Number of subjects: 6
Study: 24950912

Group type: EXPERIMENTAL
Intervention: Prospective home monitoring based on daily assessment of FEV1 and electronic symptom score
Number of subjects: 96

Group type: COMPARATOR
Intervention: Asthma Control Questionnaire (ACQ) with retrospective assessment of symptoms and FEV1
Number of subjects: 96
Study: 24951039

Group type: EXPERIMENTAL
Intervention: Non-self-reported modifiable risk factors (blood pressure, total cholesterol, high-density lipoprotein cholesterol, smoking, BMI, and HbA1c)
Number of subjects: 2359

Group type: EXPERIMENTAL
Intervention: Cardiometabolic general CVD risk model
Number of subjects: 2359
Study: 24951123

Group type: EXPERIMENTAL
Intervention: Azacitidine
Number of subjects: 302
Study: 24952265

Group type: EXPERIMENTAL
Intervention: 10-week aerobic exercise program (cycling twice a week for an hour)
Number of subjects: 26
Study: 24952730

Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (TKIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel combination therapies targeting AKT/PI3K pathways
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mTOR inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sunitinib and regorafenib (VEGFR targeting drugs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CTLA4 and PD-1/PD-L1 antibodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Older agents
Number of subjects: 0
Study: 24953487

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1617
Study: 24953566

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 100 mg/m² days 1 and 8, cisplatin 75 mg/m² day 1, 5-fluorouracil 1000 mg/m²/day for 96 hours days 1-4, every 3 weeks for three cycles
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Concurrent carboplatin (AUC 1.5 weekly) with radiation therapy (70 Gy/35 fractions)
Number of subjects: 17
Study: 24954193

Group type: EXPERIMENTAL
Intervention: Temperature acclimation at 19 °C
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Temperature acclimation at 24 °C
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Temperature acclimation at 27 °C
Number of subjects: 5